En Carta raises €5M to bring molecular testing home
En Carta Diagnostics has raised €5 million to advance at-home molecular testing, pushing sophisticated diagnostics closer to patients and away from centralised lab-only workflows.
At-home testing is moving beyond simple strips and into more sophisticated molecular diagnostics.
What happened
En Carta Diagnostics raised €5 million to advance its at-home molecular testing platform, with current product development focused on areas including Lyme disease and sexually transmitted infections. The company is working to make molecular detection available in more accessible formats outside traditional centralised laboratory settings.
Why it matters
Molecular diagnostics can offer more specific biological detection than many basic consumer tests, but the workflow has historically depended on specialised equipment and lab infrastructure. Bringing more of that capability closer to the patient could shorten testing cycles and widen access, provided performance and regulatory requirements can be met.
The bigger picture
Healthcare is gradually decentralising. Diagnostics, monitoring and treatment are moving into homes, pharmacies and other lower-friction settings, creating opportunities for startups that can translate complex clinical technology into simpler, reliable user experiences.